IL193196A - Vaccine comprising a yeast vehicle and an influenza virus fusion protein - Google Patents

Vaccine comprising a yeast vehicle and an influenza virus fusion protein

Info

Publication number
IL193196A
IL193196A IL193196A IL19319608A IL193196A IL 193196 A IL193196 A IL 193196A IL 193196 A IL193196 A IL 193196A IL 19319608 A IL19319608 A IL 19319608A IL 193196 A IL193196 A IL 193196A
Authority
IL
Israel
Prior art keywords
vaccine
protein
yeast
influenza
anyone
Prior art date
Application number
IL193196A
Other languages
English (en)
Hebrew (he)
Other versions
IL193196A0 (en
Original Assignee
Globeimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Globeimmune Inc filed Critical Globeimmune Inc
Publication of IL193196A0 publication Critical patent/IL193196A0/en
Publication of IL193196A publication Critical patent/IL193196A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16311—Influenzavirus C, i.e. influenza C virus
    • C12N2760/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IL193196A 2006-02-02 2008-07-31 Vaccine comprising a yeast vehicle and an influenza virus fusion protein IL193196A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US76502506P 2006-02-02 2006-02-02
PCT/US2007/061572 WO2007092792A2 (en) 2006-02-02 2007-02-02 Yeast-based vaccine for inducing an immune response

Publications (2)

Publication Number Publication Date
IL193196A0 IL193196A0 (en) 2011-08-01
IL193196A true IL193196A (en) 2015-01-29

Family

ID=38345897

Family Applications (2)

Application Number Title Priority Date Filing Date
IL193196A IL193196A (en) 2006-02-02 2008-07-31 Vaccine comprising a yeast vehicle and an influenza virus fusion protein
IL232518A IL232518A0 (en) 2006-02-02 2014-05-08 A yeast-based vaccine to stimulate an immune response

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL232518A IL232518A0 (en) 2006-02-02 2014-05-08 A yeast-based vaccine to stimulate an immune response

Country Status (14)

Country Link
US (2) US7736642B2 (enExample)
EP (2) EP1988919A4 (enExample)
JP (3) JP5198290B2 (enExample)
KR (2) KR20140029551A (enExample)
CN (2) CN101405026B (enExample)
AU (1) AU2007212076B2 (enExample)
BR (1) BRPI0706913A2 (enExample)
CA (1) CA2638815A1 (enExample)
IL (2) IL193196A (enExample)
IN (1) IN2014DN08830A (enExample)
MX (1) MX2008009929A (enExample)
SG (2) SG169375A1 (enExample)
TW (2) TW201412329A (enExample)
WO (1) WO2007092792A2 (enExample)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002039951A2 (en) * 2000-11-15 2002-05-23 Globe Immune, Inc. Yeast-dentritic cell vaccines and uses thereof
EP1581174B1 (en) * 2002-12-16 2018-04-25 GlobeImmune, Inc. Yeast-based vaccines as immunotherapy
US8343502B2 (en) * 2002-12-16 2013-01-01 Globeimmune, Inc. Yeast-based vaccines as immunotherapy
KR20080043775A (ko) * 2005-07-11 2008-05-19 글로브이뮨 표적 치료용 회피 돌연변이체에 대한 면역 반응의 유발방법 및 조성물
US20070172503A1 (en) * 2005-12-13 2007-07-26 Mycologics,Inc. Compositions and Methods to Elicit Immune Responses Against Pathogenic Organisms Using Yeast Based Vaccines
CN101405026B (zh) * 2006-02-02 2015-04-22 全球免疫股份有限公司 用于诱导免疫应答的基于酵母的疫苗
GB0613977D0 (en) 2006-02-07 2006-08-23 Peptcell Ltd Peptide sequences and compositions
WO2007130330A2 (en) * 2006-05-01 2007-11-15 Technovax, Inc. Polyvalent influenza virus-like particle (vlp) compositions
US20100143393A1 (en) * 2006-05-11 2010-06-10 Gale Smith Novel influenza m2 vaccines
DK2023952T3 (en) * 2006-05-18 2015-10-19 Epimmune Inc Induction of immune responses to influenza virus using polypeptide and nucleic acid compositions
BRPI0807828B8 (pt) * 2007-02-02 2021-05-25 Globeimmune Inc composição compreendendo leveduras e usos das mesmas, bem como método para o crescimento de leveduras e kit para o cultivo de leveduras
JP5579451B2 (ja) * 2007-03-19 2014-08-27 グローブイミューン，インコーポレイテッド ガンのための標的化治療の変異性回避の標的化アブレーションのための組成物
US20100285050A1 (en) 2007-10-05 2010-11-11 Isis Innovation Limited Compositions and Methods
GB0719526D0 (en) * 2007-10-05 2007-11-14 Isis Innovation Compositions and methods
WO2010036948A2 (en) * 2008-09-26 2010-04-01 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Dna prime/inactivated vaccine boost immunization to influenza virus
ES2660597T3 (es) 2009-04-17 2018-03-23 Globeimmune, Inc. Composiciones inmunoterápicas de combinación contra el cáncer y métodos
CA2762044A1 (en) * 2009-05-18 2010-11-25 Panacea Biotec Ltd Universal influenza vaccine based on recombinant modified vaccinia ankara virus (mva)
US8911722B2 (en) 2009-09-14 2014-12-16 The Regents Of The University Of Colorado, A Body Corporate Modulation of yeast-based immunotherapy products and responses
US20120015346A1 (en) * 2010-07-08 2012-01-19 New York Medical College Influenza virus detection and diagnosis
BR112013007946B1 (pt) * 2010-10-04 2022-07-12 Massachusetts Institute Of Technology Composições farmacêuticas e imunogênicas compreendendo polipeptídeos de hemaglutinina
WO2012048817A2 (en) * 2010-10-15 2012-04-19 Bavarian Nordic A/S Recombinant modified vaccinia virus ankara influenza vaccine
WO2012083302A2 (en) 2010-12-17 2012-06-21 Globeimmune, Inc. Compositions and methods for the treatment or prevention of human adenovirus-36 infection
EP2670430B1 (en) * 2011-01-31 2015-04-01 Baxter International Inc Recombinant viral vectors and methods for inducing a heterosubtypic immune response to influenza a viruses
AU2012214394B2 (en) 2011-02-12 2016-08-11 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis B infection
AU2012228937B2 (en) * 2011-03-17 2016-11-03 Globeimmune, Inc. Yeast-Brachyury immunotherapeutic compositions
CN103732249A (zh) * 2011-05-23 2014-04-16 威斯特解剖及生物研究所 含有经修饰腺病毒载体的流感疫苗
EP2720716B1 (en) 2011-06-14 2018-03-21 Globeimmune, Inc. Immunotherapeutic compositions for the treatment or prevention of hepatitis delta virus infection
AU2012273039B2 (en) * 2011-06-20 2016-12-01 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Computationally optimized broadly reactive antigens for H1N1 influenza
EP2744918A4 (en) 2011-08-17 2015-06-10 Globeimmune Inc IMMUNOTHERAPEUTIC YEAST MUC1 COMPOSITIONS AND USES THEREOF
ES2525205T3 (es) * 2011-11-09 2014-12-18 Werner Lubitz Vacuna para su uso en inmunoterapia tumoral
DE102011121069A1 (de) 2011-12-13 2013-06-13 Martin-Luther-Universität Halle-Wittenberg Vakzinierung mittels rekombinanter Hefe durch Erzeugung einer protektiven humoralen Immunantwort gegen definierte Antigene
CN104685360B (zh) 2012-06-26 2018-02-13 比奥德希克斯股份有限公司 用于选择和去选择用产生免疫应答的疗法治疗的癌症患者的质谱方法
US20140065173A1 (en) 2012-09-06 2014-03-06 Orbis Health Solutions Llc Tumor lysate loaded particles
JP5954079B2 (ja) 2012-09-25 2016-07-20 ソニー株式会社 培養観察装置及び培養観察方法
EP2929351B1 (en) * 2012-12-10 2019-10-09 The University of Queensland Cell-free biofragment compositions and related systems, devices, and methods
JP2016514672A (ja) * 2013-03-15 2016-05-23 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 抗原およびアジュバントとしてのインターロイキン−２３を有するワクチン
SG11201507328RA (en) 2013-03-19 2015-10-29 Globeimmune Inc Yeast-based immunotherapy for chordoma
TWI626948B (zh) 2013-03-26 2018-06-21 環球免疫公司 治療或預防人類免疫缺乏病毒感染之組合物及方法
JP2014210747A (ja) * 2013-04-19 2014-11-13 アンジェスＭｇ株式会社 細胞性免疫誘導能が改善された経口ワクチン
TWI654200B (zh) 2013-08-30 2019-03-21 環球免疫公司 治療或預防結核病的組合物及方法
EP4070818A3 (en) 2014-01-06 2023-01-11 The Trustees of the University of Pennsylvania Pd1 and pdl1 antibodies and vaccine combinations and use of same for immunotherapy
US10166195B2 (en) 2014-03-05 2019-01-01 Orbis Health Solutions, Llc Vaccine delivery systems using yeast cell wall particles
AU2015243256B2 (en) 2014-04-11 2020-11-05 Globeimmune, Inc. Yeast-based immunotherapy and type I interferon sensitivity
CN105233302B (zh) * 2014-07-10 2018-10-19 中国人民解放军军事医学科学院生物工程研究所 一种流感血凝素糖蛋白多聚物纳米颗粒的制备方法
US10695417B2 (en) 2015-01-09 2020-06-30 Etubics Corporation Human adenovirus serotype 5 vectors containing E1 and E2B deletions encoding the ebola virus glycoprotein
WO2016168187A1 (en) * 2015-04-13 2016-10-20 The Regents Of The University Of Michigan Virus-like particles
AU2016303525B2 (en) 2015-08-03 2021-01-21 Globeimmune, Inc. Modified yeast-Brachyury immunotherapeutic compositions
EP3334455A4 (en) * 2015-08-11 2019-08-21 Orbis Health Solutions LLC BACTERIA AND VIRUS VACCINE STRATEGY
GB2552441A (en) * 2015-10-22 2018-01-31 Royal Veterinary College Methods
EP3195878A1 (en) 2016-01-22 2017-07-26 Werner Lubitz Bacterial ghosts for the treatment of cancer
EP3475434A4 (en) 2016-03-24 2020-07-29 Nantcell, Inc. SEQUENCES AND SEQUENCES ARRANGEMENTS FOR PRESENTATION OF NEO-EPITOPIA
IL314202A (en) 2017-04-24 2024-09-01 Nantcell Inc Targeted neoepitope vectors and methods therefor
JP7382634B2 (ja) * 2017-12-21 2023-11-17 株式会社グリーンバイオメッド 交差免疫抗原ワクチン及びその調製方法
DE102017012109A1 (de) * 2017-12-27 2019-06-27 Martin-Luther-Universität Halle-Wittenberg Optimiertes Wirts-/Vektorsystem zur Erzeugung protektiver mono- und multivalenter subunit-Vakzine auf Basis der Hefe Kluyveromyces lactis
CN119818663A (zh) * 2018-05-15 2025-04-15 全球免疫公司 用于诱导细胞免疫应答的重组酵母裂解物
JP7320601B2 (ja) 2018-09-11 2023-08-03 上▲海▼市公共▲衛▼生▲臨▼床中心 広域スペクトルな抗インフルエンザワクチン免疫原及びその使用
WO2020061203A1 (en) 2018-09-21 2020-03-26 Nantcell, Inc. Methods and compositions for modulating myeloid-derived suppressor cells
JP2022532922A (ja) * 2019-05-21 2022-07-20 エスペロバックス インコーポレイティド 酵母ベースの経口ワクチン接種
EP4103722A4 (en) * 2020-02-11 2024-05-22 Cytonus Therapeutics, Inc. RAPID VACCINE PLATFORM
US12285480B2 (en) 2020-03-11 2025-04-29 Nantcell, Inc. Method of inducing immunity against SARS-CoV-2 using spike and nucleocapsid-ETSD immunogens delivered by RNA and replication-defective adenoviruses
US20210284716A1 (en) 2020-03-11 2021-09-16 Immunitybio, Inc. ACE2-Fc Trap
US11857620B2 (en) 2020-03-11 2024-01-02 Immunitybio, Inc. Method of inducing immunity against SARS-CoV-2 using spike (s) and nucleocapsid (N)-ETSD immunogens delivered by a replication-defective adenovirus
WO2021211691A1 (en) 2020-04-14 2021-10-21 Immunitybio, Inc. Yeast lysate covid-19 vaccine

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830463A (en) * 1993-07-07 1998-11-03 University Technology Corporation Yeast-based delivery vehicles
US5413914A (en) 1993-07-07 1995-05-09 The Regents Of The University Of Colorado Yeast assay to identify inhibitors of dibasic amino acid processing endoproteases
US5962298A (en) * 1994-01-11 1999-10-05 Vlaams Interuniversitair Instituut Voor Biotechnologie Influenza vaccine
US5691189A (en) * 1994-01-19 1997-11-25 Bristol-Myers Squibb Company Saccharomyces cerevisiae expressing M2 protein of influenza A virus
US6696251B1 (en) * 1996-05-31 2004-02-24 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US20020044948A1 (en) * 2000-03-15 2002-04-18 Samir Khleif Methods and compositions for co-stimulation of immunological responses to peptide antigens
BRPI0111830B8 (pt) * 2000-06-23 2021-05-25 American Cyanamid Co método de produção de partículas semelhantes ao vírus da influenza (vlps), vlps da influenza, vlps quiméricas, composições imunogênica e farmacêutica, e, usos de vlps da influenza e de vlps quiméricas
WO2002039951A2 (en) 2000-11-15 2002-05-23 Globe Immune, Inc. Yeast-dentritic cell vaccines and uses thereof
US20030008000A1 (en) * 2001-03-08 2003-01-09 Wong Jonathan P. DNA vaccine using liposome-encapsulated plasmid DNA encoding for hemagglutinin protein of influenza virus
US20030202982A1 (en) * 2001-08-15 2003-10-30 Birkett Ashley J. Influenza immunogen and vaccine
EP1581174B1 (en) * 2002-12-16 2018-04-25 GlobeImmune, Inc. Yeast-based vaccines as immunotherapy
US7439042B2 (en) * 2002-12-16 2008-10-21 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
US8592197B2 (en) * 2003-07-11 2013-11-26 Novavax, Inc. Functional influenza virus-like particles (VLPs)
WO2005116270A2 (en) * 2004-05-18 2005-12-08 Vical Incorporated Influenza virus vaccine composition and method of use
ATE536175T1 (de) * 2004-09-17 2011-12-15 Univ Massachusetts Zusammensetzungen und ihre verwendungen bei lysosomalen enzymstörungen
CN101405026B (zh) * 2006-02-02 2015-04-22 全球免疫股份有限公司 用于诱导免疫应答的基于酵母的疫苗

Also Published As

Publication number Publication date
SG10201402236VA (en) 2014-08-28
IL193196A0 (en) 2011-08-01
JP5198290B2 (ja) 2013-05-15
US20080003239A1 (en) 2008-01-03
KR20080089671A (ko) 2008-10-07
WO2007092792A3 (en) 2008-02-28
BRPI0706913A2 (pt) 2011-04-12
AU2007212076A1 (en) 2007-08-16
CN104826102A (zh) 2015-08-12
IL232518A0 (en) 2014-06-30
CA2638815A1 (en) 2007-08-16
WO2007092792A2 (en) 2007-08-16
AU2007212076B2 (en) 2012-10-18
JP2013075899A (ja) 2013-04-25
MX2008009929A (es) 2008-10-01
JP2015038147A (ja) 2015-02-26
US20100196411A1 (en) 2010-08-05
EP1988919A2 (en) 2008-11-12
US7736642B2 (en) 2010-06-15
IN2014DN08830A (enExample) 2015-07-10
KR20140029551A (ko) 2014-03-10
EP2468296A2 (en) 2012-06-27
SG169375A1 (en) 2011-03-30
TW200806316A (en) 2008-02-01
TW201412329A (zh) 2014-04-01
EP2468296A3 (en) 2013-12-04
CN101405026A (zh) 2009-04-08
KR101492524B1 (ko) 2015-02-12
EP1988919A4 (en) 2009-06-10
CN101405026B (zh) 2015-04-22
JP2009528987A (ja) 2009-08-13

Similar Documents

Publication Publication Date Title
IL193196A (en) Vaccine comprising a yeast vehicle and an influenza virus fusion protein
JP2009528987A5 (enExample)
Ansaldi et al. Cross-protection by MF59™-adjuvanted influenza vaccine: Neutralizing and haemagglutination-inhibiting antibody activity against A (H3N2) drifted influenza viruses
Eliasson et al. M2e-tetramer-specific memory CD4 T cells are broadly protective against influenza infection
JP6826027B2 (ja) インフルエンザ抗原送達用のベクターおよび構築体
Dhakal et al. Liposomal nanoparticle-based conserved peptide influenza vaccine and monosodium urate crystal adjuvant elicit protective immune response in pigs
Babapoor et al. A novel vaccine using nanoparticle platform to present immunogenic M2e against avian influenza infection
Cox Correlates of protection to influenza virus, where do we go from here?
Donnelly et al. Preclinical efficacy of a prototype DNA vaccine: enhanced protection against antigenic drift in influenza virus
Wang et al. Nanoclusters self-assembled from conformation-stabilized influenza M2e as broadly cross-protective influenza vaccines
Carrat et al. Influenza vaccine: the challenge of antigenic drift
Zheng et al. Development of universal influenza vaccines based on influenza virus M and NP genes
Lo et al. Comparison of vaccines for induction of heterosubtypic immunity to influenza A virus: cold-adapted vaccine versus DNA prime-adenovirus boost strategies
CA2632483C (en) Improved influenza vaccine
Gao et al. Enhanced Influenza VLP vaccines comprising matrix-2 ectodomain and nucleoprotein epitopes protects mice from lethal challenge
RU2015138530A (ru) Комбинированная вакцина против респираторно-синцитиального вируса и вируса гриппа
Lee et al. AS04-adjuvanted virus-like particles containing multiple M2 extracellular domains of influenza virus confer improved protection
De Jonge et al. H7N9 live attenuated influenza vaccine is highly immunogenic, prevents virus replication, and protects against severe bronchopneumonia in ferrets
CA2863981A1 (en) Computationally optimized broadly reactive antigens for h3n2, h2n2, and b influenza viruses
CA2434000A1 (en) Adjuvant viral particle
Chamtim et al. Combining segments 9 and 10 in DNA and recombinant protein vaccines conferred superior protection against tilapia lake virus in hybrid red tilapia (oreochromis sp.) compared to single segment vaccines
EP3233116A1 (en) Synergistic co-administration of computationally optimized broadly reactive antigens for h1n1 influenza
Wohlbold et al. An H10N8 influenza virus vaccine strain and mouse challenge model based on the human isolate A/Jiangxi-Donghu/346/13
Wang et al. Protective efficacy of a broadly cross-reactive swine influenza DNA vaccine encoding M2e, cytotoxic T lymphocyte epitope and consensus H3 hemagglutinin
CN103146751A (zh) 新城疫病毒株rLX/H9HA及其构建方法和应用

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
ME Application for patent revocation filed
MEA Application cancelled (applic. for patent revocation filed)

Free format text: THE OWNER OF PATENT NO. 193196 HAS REQUESTED ITS CANCELLATION. THE REQUEST IS PUBLISHED FOR OPPOSITION BY INTERESTED PARTIES.